Cargando…
Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis
Background: Cryptococcus neoformans is an encapsulated yeast that can cause fungemia and, in rare instances, lead to endogenous fungal endophthalmitis. No standard of care has been established to treat fungal endophthalmitis when systemic antifungal treatment fails to resolve the intraocular infecti...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academic Division of Ochsner Clinic Foundation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529130/ https://www.ncbi.nlm.nih.gov/pubmed/33071668 http://dx.doi.org/10.31486/toj.19.0043 |
_version_ | 1783589371614593024 |
---|---|
author | Haider, Asghar A. Gallagher, J. R. Johnson, Jordan S. Benevento, Joseph D. |
author_facet | Haider, Asghar A. Gallagher, J. R. Johnson, Jordan S. Benevento, Joseph D. |
author_sort | Haider, Asghar A. |
collection | PubMed |
description | Background: Cryptococcus neoformans is an encapsulated yeast that can cause fungemia and, in rare instances, lead to endogenous fungal endophthalmitis. No standard of care has been established to treat fungal endophthalmitis when systemic antifungal treatment fails to resolve the intraocular infection. Intravitreal voriconazole has been used for the treatment of fungal endophthalmitis caused by a broad range of fungal pathogens, and a limited number of reports have shown the efficacy of using intravitreal voriconazole for C neoformans endophthalmitis. We report a case of endogenous fungal endophthalmitis caused by C neoformans that was responsive to intravitreal voriconazole. Case Report: A previously healthy 57-year-old male diagnosed with primary neuroendocrine lung tumor developed endogenous endophthalmitis from C neoformans. The endophthalmitis was resistant to intravenous amphotericin B treatment but was responsive to intravenous fluconazole in one eye and was apparently more responsive to intravitreal voriconazole in the other eye. Conclusion: Intravitreal voriconazole should be considered for the treatment of cryptococcal endophthalmitis. |
format | Online Article Text |
id | pubmed-7529130 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Academic Division of Ochsner Clinic Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-75291302020-10-15 Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis Haider, Asghar A. Gallagher, J. R. Johnson, Jordan S. Benevento, Joseph D. Ochsner J Case Reports and Clinical Observations Background: Cryptococcus neoformans is an encapsulated yeast that can cause fungemia and, in rare instances, lead to endogenous fungal endophthalmitis. No standard of care has been established to treat fungal endophthalmitis when systemic antifungal treatment fails to resolve the intraocular infection. Intravitreal voriconazole has been used for the treatment of fungal endophthalmitis caused by a broad range of fungal pathogens, and a limited number of reports have shown the efficacy of using intravitreal voriconazole for C neoformans endophthalmitis. We report a case of endogenous fungal endophthalmitis caused by C neoformans that was responsive to intravitreal voriconazole. Case Report: A previously healthy 57-year-old male diagnosed with primary neuroendocrine lung tumor developed endogenous endophthalmitis from C neoformans. The endophthalmitis was resistant to intravenous amphotericin B treatment but was responsive to intravenous fluconazole in one eye and was apparently more responsive to intravitreal voriconazole in the other eye. Conclusion: Intravitreal voriconazole should be considered for the treatment of cryptococcal endophthalmitis. Academic Division of Ochsner Clinic Foundation 2020 2020 /pmc/articles/PMC7529130/ /pubmed/33071668 http://dx.doi.org/10.31486/toj.19.0043 Text en ©2020 by the author(s); Creative Commons Attribution License (CC BY) http://creativecommons.org/licenses/by/4.0/legalcode ©2020 by the author(s); licensee Ochsner Journal, Ochsner Clinic Foundation, New Orleans, LA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (creativecommons.org/licenses/by/4.0/legalcode) that permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Case Reports and Clinical Observations Haider, Asghar A. Gallagher, J. R. Johnson, Jordan S. Benevento, Joseph D. Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis |
title | Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis |
title_full | Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis |
title_fullStr | Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis |
title_full_unstemmed | Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis |
title_short | Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis |
title_sort | intravitreal voriconazole for the treatment of cryptococcus neoformans endogenous endophthalmitis |
topic | Case Reports and Clinical Observations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529130/ https://www.ncbi.nlm.nih.gov/pubmed/33071668 http://dx.doi.org/10.31486/toj.19.0043 |
work_keys_str_mv | AT haiderasghara intravitrealvoriconazoleforthetreatmentofcryptococcusneoformansendogenousendophthalmitis AT gallagherjr intravitrealvoriconazoleforthetreatmentofcryptococcusneoformansendogenousendophthalmitis AT johnsonjordans intravitrealvoriconazoleforthetreatmentofcryptococcusneoformansendogenousendophthalmitis AT beneventojosephd intravitrealvoriconazoleforthetreatmentofcryptococcusneoformansendogenousendophthalmitis |